Life Sciences Archives

Jun

Life Sciences

CRO Roll-Ups: Why PE Sponsors Need Better Technology Diligence

PE sponsors pursuing CRO roll-ups need Life Sciences-specific technology diligence to assess compliance, cybersecurity, validation, integration risk, and valuation impact.

IT Ally®, LLC

IT Ally® advises Lower Middle Market private equity firms, family offices, and independent sponsors on transforming technology from a hidden operational risk into a powerful Valuation Multiplier.

Powered by our proprietary Quality of Tech (QoT ™ ) methodology, we provide investor-grade diligence and execution that quantify tech debt, accelerate integration velocity, and engineer lasting equity from buy to sell.

Get Actionable Insights

Subscribe to IT Ally® Insights for sponsor-grade perspectives on technology, enterprise value, operational risk, and value creation across the investment lifecycle.

Get updates on QoT™, private equity trends, transaction advisory, and technology strategies shaping lower middle market platforms.

CRO Roll-Ups: Why PE Sponsors Need Better Technology Diligence

IT Ally®, LLC

Categories

Latest Posts

CRO Roll-Ups: Why PE Sponsors Need Better Technology Diligence

The Deal Had a Clean QoE. Six Months Later, Technology Became the Biggest Problem.

Welcome to the Era of Quality of Tech (QoTTM) & the New IT Ally

Get Actionable Insights

Quick Links